Market Minds Advisory
Robotic Biopsy Devices Market

Robotic Biopsy Devices Market: Multi-Organ Fusion Targeting and AI Guidance Dynamics

MRI-fusion robotic platforms are pulling prostate and breast biopsy volume away from freehand sampling faster than community radiology practices can afford, concentrating diagnostic value among manufacturers who can prove superior targeting accuracy.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$1.6BMarket Size 2025
2036 FORECAST VALUE$6.4BBase Case , 2026 to 2036
CAGR 2026 TO 203613.4 %Bull 14.6% / Bear 12.1%
INCREMENTAL OPPORTUNITY$4.6BNet 10- year value creation
EXPANSION MULTIPLE3.52x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Robotic biopsy devices are shifting from specialty prostate and breast applications into broader multi-organ diagnostic use as fusion imaging and robotic guidance demonstrate meaningfully higher sampling accuracy than freehand image-guided techniques. That shift is reshaping which companies attract durable clinical investment going forward. Investors are tracking this shift. closely.
AI-assisted multi-organ targeting software forms the fastest-growing segment as machine learning models trained on growing procedural datasets improve real-time lesion targeting accuracy across multiple organ systems simultaneously. North America anchors the deepest commercial concentration, reflecting dominant originator platform company headquarters presence and dense urology and interventional radiology infrastructure that developing regions still cannot fully replicate at comparable clinical scale today. That combination positions the region as the category's genuine commercial center worldwide.
Hologic and Koelis set the technology benchmark through dominant breast biopsy installed base and deep prostate fusion biopsy expertise respectively, while a fragmented tier of specialized robotics developers competes on narrow organ-specific targeting depth. Expanding fusion imaging adoption and tightening diagnostic accuracy expectations are both reshaping which companies capture procedure volume as validated targeting precision increasingly outweighs freehand technique familiarity across the category. today.
Market Definition
The robotic biopsy devices market covers robotic-assisted and fusion-guided biopsy platforms used to sample tissue from the prostate, breast, liver, kidney, and musculoskeletal structures for diagnostic evaluation, excluding lung and bronchoscopic biopsy platforms tracked as a separate category. It spans capital equipment, disposable needles and instrumentation, and targeting software sold to hospitals, imaging centers, and specialty clinics performing image-guided biopsy procedures. Freehand manual biopsy techniques without robotic or fusion guidance and unrelated surgical excisional biopsy procedures are excluded from this scope.
Base Year Value
$1.6B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
13.4% base case. Bull 14.6%. Bear 12.1%.
Fastest Growth Segment
AI-Assisted Multi-Organ Targeting Software: 19.8% CAGR
Fastest Growth Country
Japan: 15.2% CAGR
Fastest Growth Region
South Asia and Pacific: 15.4% CAGR
Largest Region
North America: 34% of 2025 global value
Market Leaders
Hologic, Koelis, Intuitive Surgical, Becton Dickinson, Perfint Healthcare. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Robotic Biopsy Devices Market Forecast Scenarios

robotic-biopsy-devices-market-size-forecast-scenario-1787305974007
Robotic biopsy devices demand grew rapidly across 2020 to 2025 as MRI-fusion prostate biopsy adoption broadened and breast biopsy robotics matured, then accelerated further as AI-assisted targeting software reached commercial validation. The market grew at an estimated 12.2% historical CAGR across the period, reflecting a genuine step change once fusion targeting evidence moved from research pilots into routine clinical workflow.
The base case assumes fusion imaging adoption continues broadening across additional organ systems through 2030, AI-assisted targeting accuracy keeps improving as procedural datasets grow, and radiology practice conversion keeps expanding as diagnostic yield evidence accumulates across major healthcare networks. Together these three mechanisms support a 13.4% forecast CAGR, with prostate robotic biopsy systems remaining the volume anchor even as AI-assisted and multi-organ formats capture growing value share each year worldwide.
The bull case centers on faster-than-expected AI targeting commercialization that pushes multi-organ adoption well ahead of current radiology practice conversion timelines. The bear case centers on renewed reimbursement scrutiny following cost-effectiveness disputes, which would slow practice adoption and compress developer valuations across cost-constrained health systems for several years as consolidation accelerates. Investors are watching this dynamic closely across major developed markets.

Fusion Targeting and Diagnostic Yield Dynamics

Robotic biopsy devices sit at the intersection of fusion imaging engineering and interventional diagnostic practice, since a platform must satisfy both mechanical targeting precision and the real-time image registration accuracy that determines whether a biopsy needle actually samples the intended lesion. That split has kept the vendor base divided between large diversified diagnostics companies and specialized robotics developers competing on organ-specific targeting depth.
TOP 5 CONCENTRATION46%share held by leading five robotic biopsy device companies
AVERAGE PROCEDURE COST$2,800 per biopsy proceduretypical disposable and instrumentation cost per completed procedure
LEADING COUNTRY SHAREUnited States, 29%share of global robotic biopsy devices commercial revenue overall
DIAGNOSTIC YIELD IMPROVEMENT31% versus freehand techniquetypical diagnostic yield improvement reported across robotic platforms
PRACTICE CONVERSION RATE22% of eligible practicesshare of eligible practices currently operating a robotic platform
AI TARGETING ADOPTION RATE14% of new proceduresshare of new procedures using AI-assisted targeting software
Commercially, the market splits between a maturing prostate and breast fusion biopsy base sold through established urology and radiology practice relationships built over years of clinical adoption, and a smaller but faster-growing multi-organ and AI-assisted tier sold on diagnostic yield rather than procedure price alone. Liver and renal biopsy platforms round out demand with organ-specific purchasing tied to interventional radiology protocol needs.
Over the next decade, targeting accuracy evidence and multi-organ software capability will matter more than raw platform installed base alone, since practices increasingly select vendors based on demonstrated diagnostic yield data rather than which supplier offers the broadest organ coverage alone. Companies that expand targeting evidence into mid-tier community practice relationships fastest stand to capture a widening share of a market that fusion accuracy is reshaping as much as procedure volume growth is.
"A biopsy needle that misses the lesion by a few millimeters isn't just an inconvenience, it's a false-negative result that delays a cancer diagnosis by months. That's the entire commercial argument for paying a premium on targeting accuracy."
Director, Interventional Diagnostics and Robotics Practice · MMA Medical Devices

Market Trends

MRI-Fusion Targeting Displaces Freehand Ultrasound Guidance

MRI-fusion robotic biopsy platforms are increasingly displacing freehand ultrasound-guided sampling as urology and radiology practices seek documented targeting accuracy that manual technique cannot reliably match, particularly for smaller or anteriorly located lesions. Koelis and Hologic have both expanded fusion targeting capacity since 2023, targeting practices that want validated diagnostic yield improvement over conventional freehand approaches. Smaller practices are adopting this technology more slowly, constrained by the capital investment required, but adoption is broadening steadily each year across major diagnostic imaging markets worldwide. Investors increasingly favor developers demonstrating consistent fusion targeting research investment.
Market Impact: Adds 6% annual biopsy-eligible volu

AI Targeting Software Extends Beyond Single-Organ Applications

AI-assisted targeting software originally developed for prostate biopsy applications is increasingly extending into breast, liver, and renal biopsy workflows, letting a single software platform support multi-organ targeting rather than requiring separate organ-specific systems. Intuitive Surgical and Perfint Healthcare have both expanded multi-organ software investment since 2023, targeting practices that want consolidated platform investment across multiple diagnostic applications. This software extension trend is broadening steadily each year across major interventional radiology programs worldwide. Investors increasingly favor developers with demonstrable multi-organ software research capability today. Adoption continues broadening steadily across major academic and community practice networks.
Market Impact: Adds 5% annual conversion volume gr

Market Opportunities and Growth Drivers

Rising Cancer Screening Volume Sustains Biopsy Demand

Global prostate and breast cancer screening volume continues rising each year as screening guideline expansion and improved imaging resolution surface more biopsy-eligible lesions, sustaining long-term demand for robotic biopsy technology regardless of near-term reimbursement cycles in any single market. This screening growth provides a durable baseline demand floor beneath the faster-growing AI targeting adoption trend layered on top of it, since underlying biopsy-eligible lesion identification continues expanding independent of specific platform technology choices. Practices increasingly prioritize screening-to-biopsy pathway coordination as a standard diagnostic investment. That opportunity compounds further each year.
Market Impact: Delays practice adoption by 14 mont

Improved Diagnostic Yield Evidence Sustains Conversion

Accumulating clinical evidence continues demonstrating that robotic and fusion-guided biopsy achieves meaningfully higher diagnostic yield than freehand technique across multiple organ systems, sustaining long-term conversion demand regardless of near-term practice capital budget cycles in any single market. This outcomes evidence growth provides a durable baseline demand floor beneath the faster-growing multi-organ platform trend layered on top of it, since underlying practice confidence in fusion-guided technique continues strengthening independent of specific platform choices. Practices increasingly view yield transparency as a genuine competitive differentiator. Adoption continues broadening steadily. today. across major markets.
Market Impact: Delays approval by 18 months

Market Restraints and Challenges

High Platform Cost Limits Broader Community Practice Adoption

Robotic biopsy platform capital equipment pricing remains substantially higher than conventional freehand ultrasound-guided instrumentation costs, creating a purchasing barrier for smaller community practices even when procedural volume projections would otherwise justify the investment on a per-procedure economics basis. This constraint is particularly burdensome for practices lacking the annual biopsy procedure volume needed to achieve favorable capital equipment utilization economics relative to larger academic radiology departments. Companies are responding by expanding flexible leasing and per-procedure fee structures that reduce the upfront capital barrier for smaller practices. today. Adoption continues broadening steadily.
Market Impact: Adds $420 per fusion-guided procedu

Multi-Organ Validation Complexity Slows New Platform Approval

Validating a multi-organ targeting platform requires extensive organ-specific clinical testing to confirm that targeting accuracy holds across substantially different anatomic and tissue characteristics, creating a lengthy validation pathway that takes considerably longer than validating a single-organ platform alone. This requirement is particularly burdensome for smaller developers lacking the clinical trial infrastructure and regulatory relationships that larger established companies maintain internally for faster multi-organ validation turnaround. Companies are responding by investing in expanded validation capability and pursuing platform-based approaches that can support multiple organ applications simultaneously. today. Adoption continues broadening steadily.
Market Impact: Cuts per-organ software cost by 28%
3 additional market trends, 3 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Robotic biopsy devices segment by organ and application type, the classification practices and payers use to set purchasing tier, targeting accuracy expectations, and reimbursement pathway, since prostate, breast, and multi-organ buyers each negotiate under distinct clinical terms. Vendors price each category differently depending on targeting sophistication and organ complexity involved. across the broader industry.
robotic-biopsy-devices-market-market-share-analysis-1787305974542

AI-Assisted Multi-Organ Targeting Software

AI-assisted multi-organ targeting software forms the fastest-growing segment as machine learning models trained on growing procedural datasets improve real-time lesion targeting accuracy across multiple organ systems simultaneously rather than requiring separate organ-specific platforms. Intuitive Surgical and Perfint Healthcare have both expanded multi-organ software investment since 2023, targeting practices that want consolidated platform investment across prostate, breast, and abdominal applications. Companies that secure early clinical validation are capturing procedure volume from competitors that lack comparable multi-organ targeting accuracy data, an advantage that compounds as more practices standardize around a smaller set of trusted consolidated platforms. If software validation continues at the current pace, this segment could approach a meaningful share of total category value within the next several years.
CAGR 19.8%

Prostate Robotic Biopsy Systems

Prostate robotic biopsy systems form the second-fastest segment as MRI-fusion targeting increasingly displaces freehand transrectal ultrasound sampling given documented accuracy advantages for smaller or anteriorly located lesions that freehand technique often misses. Koelis and Hologic have both expanded prostate fusion targeting capacity since 2023, targeting urology practices that want validated diagnostic yield improvement over conventional approaches. Practices that adopt fusion targeting early are capturing referral volume from competitors lacking comparable accuracy data, an advantage that compounds as more referring physicians favor practices with proven diagnostic yield performance across their broader patient populations. Payers increasingly view this segment as a durable long-term differentiator worth monitoring closely. That trajectory should continue strengthening as more practices adopt validated fusion protocols.
CAGR 16.4%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Robotic biopsy devices commercial activity concentrates where originator platform company headquarters and interventional diagnostic infrastructure are most developed, even though underlying cancer screening volume runs globally distributed rather than concentrated in any particular region each year. particularly across major platform origin and diagnostic infrastructure markets tracked globally.

North America

The United States accounts for the overwhelming majority of North America's robotic biopsy devices commercial value, reflecting dominant originator platform company headquarters presence and dense urology and interventional radiology infrastructure supporting broad fusion biopsy adoption, a combination that pushes the region above its default commercial share band, reflecting a genuine platform origin concentration rather than a default geographic assumption. Canada contributes a smaller but meaningful share through its established academic radiology infrastructure. Fusion targeting adoption runs meaningfully ahead of the global average across most large urology practice networks in the region. Venture funding concentration continues reinforcing this advantage each year across major biotechnology and robotics hubs nationwide. That consolidation trend continues strengthening steadily each year across the sector.
Share: 34% | CAGR: 12.8% (2026 to 2036)

Western Europe

Germany, France, and the United Kingdom together anchor Western Europe's robotic biopsy devices demand, reflecting well-established national health system radiology infrastructure and comparatively cautious health technology assessment evaluation of premium-priced fusion platforms relative to United States purchasing pathways. Regulatory approval timelines for advanced targeting platforms across the European Union proceed somewhat more deliberately than the accelerated United States pathway, delaying broad regional adoption. Smaller Western European markets rely more heavily on centralized reference diagnostic centers rather than distributed community practice networks. Smaller Western European markets rely more heavily on centralized reference diagnostic centers, concentrating advanced platform volume at fewer high-throughput facilities each year. Regional academic training programs continue expanding fusion targeting curricula each year.
Share: 21% | CAGR: 11.8% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
robotic-biopsy-devices-market-country-cagr-analysis-1787305975062

Where Diagnostic Value Concentrates Next

Revenue growth in robotic biopsy devices increasingly depends on capturing AI-assisted targeting accuracy, multi-organ platform consolidation, and community practice expansion rather than raw single-organ procedure volume alone, since diagnostic yield evidence, not raw platform installed base, is reshaping where value concentrates across the industry today. The levers below outline where that value is concentrating fastest across the industry today.

Expanding AI-Assisted Multi-Organ Targeting Capability Further

Companies expanding AI-assisted multi-organ targeting capability are capturing practice relationships that single-organ-only competitors cannot fulfill, particularly as more practices face growing demand for consolidated platform investment across diagnostic applications. Building competitive multi-organ targeting capability typically costs $24 million to $52 million in data science, clinical validation, and regulatory submission investment. Companies without adequate software investment increasingly lose practice relationships to better-evidenced competitors offering broader organ coverage sooner. Adoption continues broadening steadily as practices seek consolidated platform investment. Adoption continues broadening steadily as more practices seek consolidated platform investment. today. now.
Market Impact: Costs $24 to $52 million to fully b

Building Community Practice Access Programs Now

Companies building dedicated community practice access programs are capturing procedure volume that academic-only competitors cannot fulfill, particularly as more mid-tier practices face growing pressure to offer fusion-guided diagnostic capability. Developing competitive community access programs typically costs $12 million to $28 million in flexible financing, training infrastructure, and support staff investment. Companies with superior access programs increasingly win practice preference from competitors offering only traditional capital purchase alternatives. Adoption continues broadening steadily as practices seek accessible platform financing. Adoption continues broadening steadily as more practices seek accessible platform financing. today. now.
Market Impact: Costs $12 to $28 million to fully b

Securing Large Diagnostic Network Equipment Contracts

Companies securing dedicated equipment contracts with large diagnostic imaging networks are capturing volume growth that transactional individual practice relationships cannot match on scale and long-term purchasing commitment. These partnerships typically carry a 15 to 24% margin premium given the coordinated procurement and training support networks provide. Companies able to demonstrate reliable targeting accuracy increasingly win these contracts over less-prepared competitors seeking similar network access. Adoption continues broadening steadily as networks seek coordinated equipment relationships. Adoption continues broadening steadily as more networks seek coordinated equipment relationships. That advantage compounds each successive year.
Market Impact: Commands a 15 to 24% margin premium

Investing In Organ-Specific Clinical Evidence Generation

Companies investing in organ-specific clinical evidence generation are positioned to capture practice adoption volume from clinicians seeking documented diagnostic yield data before switching from established freehand techniques. Developing competitive evidence generation capability typically costs $16 million to $34 million in clinical trial design, data infrastructure, and regulatory submission investment. Companies with strong evidence generation increasingly win faster practice adoption from clinicians still evaluating broader platform trust and reliability data. Adoption continues broadening steadily as more clinicians seek documented diagnostic yield data. That advantage compounds each successive year across the category.
Market Impact: Costs $16 to $34 million to fully b

Who Controls the Margin Pool

The top five vendors hold an estimated 46% of global robotic biopsy devices revenue, a moderate concentration reflecting the category's mix of organ-specialized companies and broader diagnostics developers still building toward multi-organ commercial scale. Hologic and Koelis lead on breast biopsy installed base and prostate fusion expertise respectively, while a fragmented tier of specialized robotics developers competes on narrow organ-specific targeting depth.
Current competitive activity centers on three fronts. AI-assisted multi-organ targeting development is opening a new front for companies willing to invest ahead of confirmed broader clinical adoption. Community practice access program development is becoming increasingly important as companies compete for procedure volume beyond academic-center-only relationships. And several mid-sized developers are pursuing large diagnostic network equipment contracts to differentiate beyond commoditized individual practice sales.

Emerging pressure comes from specialized robotics developers advancing multi-organ targeting candidates as they partner with academic medical centers and imaging equipment manufacturers, though matching Hologic or Koelis's installed base and clinical expertise remains years away for most. If these challengers close that gap, expect share to shift within specific organ categories first, before pressure reaches the largest diversified incumbents. That competition continues intensifying steadily across the broader category each year.
robotic-biopsy-devices-market-company-positioning-matrix-1787305975592

Competitive Moat and Risk Dimensions

HOLOGIC INC.

Moat: Dominant Breast Biopsy Installed Base

Hologic maintains one of the industry's dominant breast biopsy platform installed bases, built through decades of continuous investment establishing stereotactic biopsy technology as the default choice across major breast imaging centers worldwide. That installed base gives Hologic a durable prescribing and referral advantage that smaller competitors without comparable market history cannot quickly replicate.
HOLOGIC INC.

Risk: Narrow Single-Organ Revenue Concentration

Hologic's revenue concentration in breast biopsy technology creates meaningful exposure to competitive entry from broader multi-organ developers whose diversified pipelines could erode its narrow organ-specific focus over time. If competing multi-organ categories demonstrate faster growth, Hologic risks losing relative market relevance despite its dominant position within its core category.
KOELIS SAS

Moat: Deep Prostate Fusion Biopsy Expertise

Koelis maintains deep prostate fusion biopsy expertise built through years of continuous clinical research establishing MRI-fusion targeting as a validated standard among urology practices seeking documented diagnostic yield improvement. That expertise gives Koelis a durable credibility advantage among urologists evaluating fusion platform purchasing decisions. That credibility depth compounds with each successive clinical study.
KOELIS SAS

Risk: Smaller Scale Versus Diversified Competitors

Koelis' smaller scale relative to diversified competitors like Hologic and Intuitive Surgical constrains its capital access for large-scale multi-organ expansion investment during periods of intensifying competitive pressure. If category growth requires faster capital deployment than Koelis' scale allows, it risks losing pace to better-capitalized rivals.

Players Tracked

Prominent Players

Hologic Inc.
Koelis SAS
Intuitive Surgical Inc.
Becton Dickinson and Company
Perfint Healthcare Corporation

Other Key Players

Devicor Medical Products Inc.
Merit Medical Systems Inc.
IZI Medical Products LLC
EDAP TMS SA
Biobot Surgical Pte Ltd.
Trod Medical
Micrima Limited
Hitachi Ltd.
Canon Medical Systems Corporation
Siemens Healthineers AG
Koninklijke Philips N.V.
GE HealthCare Technologies Inc.
Fujifilm Holdings Corporation
Argon Medical Devices Inc.
BK Medical Holding Company Inc.

Recent Developments

APRIL 2025

Koelis Expands AI-Assisted Targeting Software Capability

Koelis announced expanded AI-assisted targeting software capability to improve real-time lesion tracking accuracy during live procedures, following clinical validation studies demonstrating meaningful diagnostic yield improvement across multiple practice sites. The expansion followed multi-year data science investment across several academic partnerships. Analysts expect similar programs from other qualified competitors soon.
Signal: Confirms AI-assisted targeting capability
OCTOBER 2024

Hologic Signs Multi-Year Diagnostic Network Agreement

Hologic secured a multi-year equipment supply agreement with a major diagnostic imaging network, guaranteeing platform access and coordinated training through 2029 across several affiliated breast imaging programs. The agreement reflects networks' push to lock in reliable diagnostic partnerships ahead of expanding procedure volume. today. today.
Signal: Shows diagnostic networks prioritizing lon
JANUARY 2025

Perfint Healthcare Announces Multi-Organ Platform Expansion

Perfint Healthcare announced an expanded multi-organ targeting platform designed to support prostate, liver, and renal biopsy applications within a single consolidated system. Similar multi-organ expansion programs are expected across other qualified competitors over the coming year as demand grows. Analysts expect similar expansion programs to follow soon industry-wide.
Signal: Signals multi-organ platform consolidation

Precision Robotics and Imaging Software Cost Pressure

Precision robotics components and imaging registration software development together account for roughly 41% of effective cost of goods for robotic biopsy device companies, given the specialized actuator engineering and extensive fusion imaging algorithm development required for reliable real-time targeting accuracy. Disposable needle and instrumentation manufacturing costs add a further meaningful share, particularly for companies developing multi-organ platform capability.
Precision robotics component and software development costs rose meaningfully following 2022 global semiconductor supply disruption, with several companies reporting input cost increases exceeding 18% before pricing stabilized through 2023 and into 2024. Industry supply chain reviews have flagged precision actuator component availability as this market's single most concentrated cost driver, more than software development or disposable manufacturing costs combined. Several companies have flagged component supply volatility as an ongoing operational risk.

Smaller specialty developers without long-term component supply agreements absorbed the 2022 cost increases hardest, losing practice contract bids to larger competitors including Hologic and Koelis that had negotiated priority supplier allocation years in advance. Companies with secured component supply weathered the cost increases far better than those dependent on spot market purchasing, a cost advantage that persists most sharply across smaller specialty developers today.
robotic-biopsy-devices-market-cost-volatility-analysis-1787305975793

Long-Term Component Supplier Agreements Secure Pricing

Companies increasingly negotiate multi-year precision robotics component supply agreements with priority allocation clauses, reducing exposure to spot market price volatility during periods of broader semiconductor supply disruption. This approach has helped several companies maintain more stable platform pricing during periods of input cost inflation today. Several suppliers now offer flexible volume tiers for smaller manufacturers.

Shared Software Development Infrastructure Lowers Fixed Cost

Smaller specialty developers increasingly share machine learning model training infrastructure through cloud computing partnership arrangements, spreading fixed computing cost across broader development volume than any single smaller developer could support alone economically. This shared infrastructure model has helped smaller developers remain competitive against larger companies. Several developers report significantly faster time-to-market using this shared approach.

Vertical Integration Into Instrument Manufacturing Reduces Exposure

Several larger companies are investing in direct disposable instrument manufacturing capability to reduce dependence on third-party component suppliers, gaining pricing control and supply security that non-integrated competitors cannot match during periods of tightening capacity. This integration also reduces exposure to spot market volatility. This structure increasingly appeals to companies seeking supply security today. today.

Portfolio Architecture for Margin Defence

Robotic biopsy devices portfolios span three margin tiers, from commodity-adjacent standard single-organ platforms sold largely on price, through certified fusion-guided systems carrying evidence-driven premiums, toward an emerging next-generation tier built around AI-assisted multi-organ platforms still gaining share. Gross margin widens meaningfully at each tier as targeting sophistication and clinical evidence depth increase, reflecting growing willingness to pay for proven diagnostic yield.
The volume versus premium tension centers on software and clinical investment allocation. Companies must choose between dedicating capital to high-margin AI-assisted and multi-organ programs with growing but still-smaller volume, or serving reliable standard single-organ demand that fills out most procedure volume across a typical year. Companies without spare capital increasingly favor higher-margin next-generation programs where competition remains comparatively thin still. That tension continues shaping capital allocation decisions across the industry each year.

High-value margin pools concentrate in AI-assisted and multi-organ platforms with completed clinical validation, where software investment and evidence depth keep competition thin and practices pay a premium for proven diagnostic yield certainty. Standard single-organ platforms remain the volume anchor but carry thinner margins across the portfolio, leaving smaller companies with fewer diversification options than larger integrated competitors today. today.

Volume / Commodity-Adjacent Tier

Standard single-organ fusion biopsy platforms sold largely on price and practice purchasing relationships without multi-organ-driven premiums, across most standard buyer segments worldwide. Pricing pressure from practice purchasing committees keeps margins comparatively thin across this tier.
Gross Margin: 22-32%

Premium / Certified Tier

Validated fusion-guided systems sold under practice contracts carrying evidence-driven pricing power built through years of proven diagnostic yield performance. Practices increasingly compare targeting accuracy data before committing to a long-term relationship.
Gross Margin: 38-50%

Sustainability / Regulatory / Next-Generation Tier

AI-assisted multi-organ platforms in active premium adoption, commanding premium pricing against limited proven alternatives as clinical evidence and targeting sophistication expand across major markets. Companies with the deepest evidence and technical capability capture most of this premium value today.
Gross Margin: 44-56%
robotic-biopsy-devices-market-portfolio-architecture-1787305976301

High-value Sub-segments and Strategic Watch-out

AI-Assisted Multi-Organ Targeting Software

Fastest-growing and highest long-term value pool as practices adopt consolidated targeting under expanding validation and narrowing accuracy gaps, though growth remains concentrated in well-resourced practice relationships rather than the broader market. Intuitive Surgical and Perfint Healthcare are among those actively expanding capability today. That advantage compounds each year.
Gross Margin: 42-54%

Prostate Robotic Biopsy Systems

High-value pool growing steadily as urology practices adopt fusion targeting, particularly across academic urology centers where diagnostic yield demand has increased meaningfully since 2023 across multiple facility types. Koelis and Hologic continue expanding capacity, reinforcing this segment's growth trajectory over time. Investors increasingly track adoption metrics closely across this segment.
Gross Margin: 36-48%

Breast Robotic Stereotactic Biopsy Systems

Steady volume core segment tied to standard breast imaging workflows, carrying moderate margins below AI-assisted and prostate tiers but anchoring most company revenue across the industry consistently each year. Smaller practices continue relying on standard platforms today. This segment anchors baseline company revenue across the broader industry today.
Gross Margin: 22-32%

Capital-Constrained Community Practice Segment

Strategic watch-out segment facing a persistent adoption ceiling as high capital equipment cost leaves companies dependent on flexible financing buildout rather than guaranteed broad practice access nationwide. Companies serving this segment increasingly fund financing programs to offset this gap. That ceiling persists until financing investment accelerates industry-wide.
Gross Margin: 18-28%

Recurring Per-Procedure Disposable Relationship

Robotic biopsy devices purchasing functions closer to a recurring annuity than a single transaction for practices, since a platform capital equipment purchase typically locks in disposable needle and software licensing revenue across every subsequent procedure for the life of the equipment relationship rather than any per-procedure vendor selection decision. Individual screening-driven referral events behave differently, occurring at discrete diagnostic points rather than following any predictab
Adoption depth varies sharply by end-use vertical. Academic medical centers and large diagnostic imaging networks show the deepest engagement with AI-assisted and multi-organ platforms, given dedicated interventional staff and technical sophistication, while smaller community practices adopt more slowly since platform investment rarely gets justified by comparatively low individual procedure volume. That divide shapes where companies concentrate commercial and financing investment.

A generational shift is underway as younger urologists and radiologists, trained during the era of routine fusion-guided technique availability, evaluate platform partners on diagnostic yield data and multi-organ capability rather than decades-long familiarity with conventional freehand approaches alone. That openness gives evidence-forward companies a rare opening to win practice share in a category where legacy technique relationships have otherwise been difficult to dislodge.
robotic-biopsy-devices-market-end-use-penetration-index-1787305976791

Where MMA Sees The Opportunity

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / AI TARGETING INVESTMENT

Expand Multi-Organ Software Before Demand Fully Peaks

Practices are increasingly requiring validated multi-organ targeting capability before adopting a company as their primary diagnostic partner, and companies without adequate software investment are losing practice relationships to better-equipped competitors as this shift accelerates. Software investment requires meaningful upfront capital but opens durable practice relationships that single-organ-constrained competitors cannot match once multi-organ demand fully materializes. Companies waiting until demand fully peaks will find themselves racing to catch up against incumbents who invested years earlier, a gap that widens each quarter software investment lags behind competitor programs already underway.
02 / COMMUNITY ACCESS INVESTMENT

Build Practice Financing Before Standards Fully Harden

Community practices have not universally committed to a single fusion platform financing standard, leaving a genuine opportunity for companies willing to fund accessible programs ahead of confirmed industry standardization trends. Waiting for financing standards to formally standardize risks missing the commercial differentiation window entirely once a preferred access model forms across practice networks. The investment required is meaningful but positions early movers to capture a category growing faster than academic-only adoption pathways today, a window that will not stay open indefinitely.
03 / DIAGNOSTIC NETWORK PARTNERSHIP DEVELOPMENT

Pursue Network Contracts Before Vendor Consolidation Peaks

Large diagnostic imaging network equipment consolidation has repeatedly rewarded early-mover companies first, and companies without dedicated partnership strategies risk ceding this growing category volume to competitors who invest in coordinated relationships earlier. Network partnerships represent a meaningful growth opportunity even though individual practice sales currently drive most category revenue. Companies pursuing partnership development now, while competitive density remains manageable, protect volume against the next wave of vendor consolidation reshaping network equipment decisions, gaining durable advantage as consolidation continues reshaping the category.
04 / REGIONAL ACCESS INVESTMENT

Prioritize South Asia and East Asia Access Investment Now

South Asia and Pacific and East Asia carry rapidly growing cancer screening infrastructure investment relative to their current commercial robotic biopsy devices value, as private healthcare access and robotics manufacturing accelerate across India, China, and neighboring markets. Companies concentrating capacity expansion solely around legacy Western practice relationships risk ceding share in the regions where volume growth will be steepest through 2036. Early investment in regional manufacturing and distribution partnerships offers a meaningful head start over competitors still anchored entirely to legacy Western customer bases.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Robotic Biopsy Devices Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Robotic Biopsy Devices Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized regional urology practice network operating multiple clinic locations across a major United States metropolitan area, performing a large annual volume of prostate biopsy procedures. The network reported annual clinical services revenue of approximately $85 million (client-reported, unverified by MMA) and was evaluating whether to invest in MRI-fusion robotic biopsy capability ahead of anticipated demand or continue with freehand technique instead.
STRATEGIC CHALLENGE
Leadership needed to decide whether investing in MRI-fusion robotic biopsy capability, which carried meaningful capital and staff training investment cost, would generate sufficient diagnostic yield and referral benefits to justify the investment relative to continuing with existing freehand ultrasound-guided protocols. Competing regional urology practices were beginning to adopt fusion platforms and evaluating vendor options.
MMA APPROACH
MMA benchmarked the client's platform investment options against comparable urology practices that had already adopted MRI-fusion robotic biopsy capability, modeling diagnostic yield impact and referral growth against implementation timing and vendor selection criteria. The analysis incorporated primary survey data from urology practice administrators at nine comparable regional networks. Findings were cross-checked against yield benchmarks published in recent industry surveys.
KEY FINDINGS
  1. Diagnostic yield improvement from early fusion platform adoption exceeded management's initial projections once staff workflow redesign was properly incorporated into the operational model used for this analysis.
  2. Peer practices that adopted fusion platforms early reported measurably stronger referring physician satisfaction than practices relying entirely on freehand technique workflows exclusively.
  3. Platform investment payback occurred faster than initially budgeted once reduced repeat biopsy costs were properly incorporated into the financial model used for this specific transition.
  4. Continuing freehand-only technique carried a quantifiable competitive risk as referring physicians increasingly viewed documented diagnostic yield as a marker of overall practice quality.
CLIENT PROFILE
The client is a mid-sized regional urology practice network operating multiple clinic locations across a major United States metropolitan area, performing a large annual volume of prostate biopsy procedures. The network reported annual clinical services revenue of approximately $85 million (client-reported, unverified by MMA) and was evaluating whether to invest in MRI-fusion robotic biopsy capability ahead of anticipated demand or continue with freehand technique instead.
STRATEGIC CHALLENGE
Leadership needed to decide whether investing in MRI-fusion robotic biopsy capability, which carried meaningful capital and staff training investment cost, would generate sufficient diagnostic yield and referral benefits to justify the investment relative to continuing with existing freehand ultrasound-guided protocols. Competing regional urology practices were beginning to adopt fusion platforms and evaluating vendor options.
MMA APPROACH
MMA benchmarked the client's platform investment options against comparable urology practices that had already adopted MRI-fusion robotic biopsy capability, modeling diagnostic yield impact and referral growth against implementation timing and vendor selection criteria. The analysis incorporated primary survey data from urology practice administrators at nine comparable regional networks. Findings were cross-checked against yield benchmarks published in recent industry surveys.
KEY FINDINGS
  1. Diagnostic yield improvement from early fusion platform adoption exceeded management's initial projections once staff workflow redesign was properly incorporated into the operational model used for this analysis.
  2. Peer practices that adopted fusion platforms early reported measurably stronger referring physician satisfaction than practices relying entirely on freehand technique workflows exclusively.
  3. Platform investment payback occurred faster than initially budgeted once reduced repeat biopsy costs were properly incorporated into the financial model used for this specific transition.
  4. Continuing freehand-only technique carried a quantifiable competitive risk as referring physicians increasingly viewed documented diagnostic yield as a marker of overall practice quality.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 5): Select a fusion platform partner and begin staff training ahead of formal validation testing across pilot case types. Phase 2: Phase 2 (Months 6 to 12): Complete clinical validation and launch the platform across full procedure volume while tracking diagnostic yield against the modeled benchmark closely. Phase 3: Phase 3 (Months 13 to 20): Expand platform capability to additional organ applications to capture broader efficiency benefits once initial performance is confirmed.
OUTCOME
Within twelve months of launch, the client reported diagnostic yield improvement of approximately 27% (client-reported, unverified by MMA), exceeding initial projections meaningfully. Referring physician satisfaction scores improved measurably (client-reported, unverified by MMA), and the network now serves as a regional reference site for smaller urology practices.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Robotic Biopsy Devices Market?

The robotic biopsy devices market was valued at approximately $1.60 billion in 2025. Growth is driven primarily by MRI-fusion targeting adoption and expanding AI-assisted multi-organ software.

How large will the Robotic Biopsy Devices Market be by 2036?

The market is forecast to reach approximately $6.38 billion by 2036, roughly 3.52 times its 2026 value as AI-assisted and multi-organ formats broaden globally. Growth reflects broadening AI-assisted and multi-organ adoption.

What is the CAGR for the Robotic Biopsy Devices Market 2026 to 2036?

The market is forecast to grow at a 13.4% CAGR between 2026 and 2036. Bull and bear scenarios range from roughly 12.1% to 14.6% depending on adoption pace and reimbursement conditions.

Which segment is growing fastest?

AI-assisted multi-organ targeting software is the fastest-growing segment at approximately 19.8% CAGR, roughly 1.48 times the overall market growth rate. Prostate robotic biopsy systems follow as the second-fastest segment.

Who are the major companies in the Robotic Biopsy Devices Market?

Leading companies include Hologic, Koelis, Intuitive Surgical, Becton Dickinson, and Perfint Healthcare, together holding an estimated 46% of global commercial revenue. Smaller specialized developers make up the remaining share.

Which country is growing fastest?

Japan is the fastest-growing country at approximately 15.2% CAGR, driven by strong government investment in interventional diagnostic infrastructure. The United States still commands the largest overall share of commercial value.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Organ and Application Type

  • Prostate Robotic Biopsy Systems
  • Breast Robotic Stereotactic Biopsy Systems
  • Liver and Abdominal Robotic Biopsy Systems
  • Renal Robotic Biopsy Systems
  • Musculoskeletal and Soft-Tissue Robotic Biopsy Systems
  • AI-Assisted Multi-Organ Targeting Software

By End-Use Care Setting

  • Academic Medical Centers
  • Community Urology and Radiology Practices
  • Diagnostic Imaging Networks
  • Specialty Cancer Centers

By Commercial Dimension

  • Capital Equipment Direct Purchase
  • Flexible Leasing and Financing Programs
  • Per-Procedure Fee Arrangements
  • Software Licensing and Subscription Sales

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The robotic biopsy devices market covers robotic-assisted and fusion-guided biopsy platforms used to sample tissue from the prostate, breast, liver, kidney, and musculoskeletal structures for diagnostic evaluation, excluding lung and bronchoscopic biopsy platforms tracked as a separate category. It spans capital equipment, disposable needles and instrumentation, and targeting software sold to hospitals, imaging centers, and specialty clinics performing image-guided biopsy procedures. Freehand manual biopsy techniques without robotic or fusion guidance and unrelated surgical excisional biopsy procedures are excluded from this scope.
Quantitative Units
USD billions (current prices); procedure volume in thousands where applicable
Segmentation Dimensions
By Organ and Application Type; By End-Use Care Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Malaysia, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Hologic Inc., Koelis SAS, Intuitive Surgical Inc., Becton Dickinson and Company, Perfint Healthcare Corporation, Devicor Medical Products Inc., Merit Medical Systems Inc., IZI Medical Products LLC, EDAP TMS SA, Biobot Surgical Pte Ltd., Trod Medical, Micrima Limited, Hitachi Ltd., Canon Medical Systems Corporation, Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Fujifilm Holdings Corporation, Argon Medical Devices Inc., BK Medical Holding Company Inc.
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-171
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Robotic Biopsy Devices Market Report (2026 to 2036).

This report analyzes the global robotic biopsy devices market, covering prostate, breast, and multi-organ segments across all seven MMA-tracked global regions. It includes detailed market sizing and forecasts through 2036, competitive benchmarking of the top twenty vendors across organ-specialized companies and broader diagnostics developers, and segment-level analysis of AI-assisted targeting adoption. The report draws on MMA's primary survey of 3,800 respondents and 47 expert interviews conducted in the fourth quarter of 2025, supplemented by company disclosures and government health agency data. Buyers receive full access to regional data tables, competitive profiles, and strategic recommendations tailored to developers, diagnostic networks, and medical device investors worldwide.
Full seven-region market sizing and forecast data
Competitive benchmarking of twenty profiled industry vendors
Segment-level analysis of AI-assisted targeting adoption trends
Primary survey data from 3,800 global respondents
Expert interview insights from 47 interventional diagnostics specialists
Strategic recommendations for developers and diagnostic networks

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts